BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30498981)

  • 1. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
    Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
    Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
    Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
    BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
    Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
    Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
    Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair gets physical: mapping an XPA-binding site on ERCC1.
    Croteau DL; Peng Y; Van Houten B
    DNA Repair (Amst); 2008 May; 7(5):819-26. PubMed ID: 18343204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
    Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
    ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
    Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
    J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif.
    Fadda E
    Biophys J; 2013 Jun; 104(11):2503-11. PubMed ID: 23746523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
    Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
    Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer.
    An HJ; Jo H; Jung CK; Kang JH; Kim MS; Sun DI; Cho KJ; Cho JH; Won HS; Sun S; Ko YH
    Pathol Res Pract; 2017 Aug; 213(8):949-955. PubMed ID: 28645807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment.
    Jagdis A; Phan T; Klimowicz AC; Laskin JJ; Lau HY; Petrillo SK; Siever JE; Thomson TA; Magliocco AM; Hao D
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1340-5. PubMed ID: 23182703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
    Jiang H; Yang LY
    Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF beta promotes repair of bulky DNA damage through increased ERCC1/XPF and ERCC1/XPA interaction.
    Zheng H; Jarvis IWH; Bottai M; Dreij K; Stenius U
    Carcinogenesis; 2019 Jun; 40(4):580-591. PubMed ID: 30418489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
    De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
    Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
    Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
    Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ERCC1 and ERCC4 (XPF) genes and gene products.
    Manandhar M; Boulware KS; Wood RD
    Gene; 2015 Sep; 569(2):153-61. PubMed ID: 26074087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.